Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

C2800000

Cortisone acetate

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Cortisone 21-acetate, 17α,21-Dihydroxy-4-pregnene-3,11,20-trione 21-acetate, 21-Acetoxy-4-pregnen-17α-ol-3,11,20-trione, 4-Pregnene-17α,21-diol-3,11,20-trione 21-acetate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C23H30O6
Numero CAS:
50-04-4
Peso molecolare:
402.48
Beilstein:
2067543
Numero MDL:
MFCD00003609
Codice UNSPSC:
41116107
ID PubChem:
329774751
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

cortisone

Produttore/marchio commerciale

EDQM

Punto di fusione

237-240 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])C(=O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)COC(C)=O

InChI

1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
ITRJWOMZKQRYTA-RFZYENFJSA-N

Informazioni sul gene

human ... NR3C1(2908)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Cortisone acetate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

Health hazard
GHS08

Avvertenze

Warning

Indicazioni di pericolo

H361d

Classi di pericolo

Repr. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

L Barbetta et al.
Journal of endocrinological investigation, 28(7), 632-637 (2005-10-13)
Since the optimal glucocorticoid replacement needs to avoid over and under treatment, the adequacy of different daily cortisone acetate (CA) doses was assessed in 34 patients with primary and central hypoadrenalism. The conventional twice CA 37.5 mg/day dose was administered
Ricardo P P Moreira et al.
Clinics (Sao Paulo, Brazil), 66(8), 1361-1366 (2011-09-15)
21-hydroxylase deficiency is an autosomal recessive disorder that causes glucocorticoid deficiency and increased androgen production. Treatment is based on glucocorticoid replacement; however, interindividual variability in the glucocorticoid dose required to achieve adequate hormonal control has been observed. The present study
B Ekman et al.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 42(13), 961-966 (2010-10-07)
Our aim was to investigate the usefulness of circulating levels of adrenocorticotropic hormone (ACTH) and also salivary cortisol to monitor cortisone substitution in patients with Addison's disease. 13 patients with primary adrenal insufficiency (8 women and 5 men, age 44
K Løvås et al.
Journal of endocrinological investigation, 29(8), 727-731 (2006-10-13)
No ideal parameter is available for assessment of the glucocorticoid replacement therapy in Addison's disease. Serum cortisol day-curves can be used to monitor the therapy, but this technique is cumbersome and expensive. We evaluated the potential for saliva cortisol measurement
C Kristo et al.
Journal of endocrinological investigation, 31(5), 400-405 (2008-06-19)
Cardiovascular disease has been reported to be more common in patients with endogenous Cushing's syndrome (CS) compared to the normal population. In addition to altered lipid profile, inflammation seems to play an important pathogenic role in atherogenesis, but the role
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.